Compare Abbott Laboratories (ABT) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while YieldMax MSTR Option Income Strategy ETF trades at $12.88. The key difference: Abbott Laboratories pays a 2.63% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABT | MSTY | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $114.30 |
52-Week Low | $82.57 | $11.55 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MSTY trades at $13.64, up 0.44% today, with a bearish technical outlook indicated by moving averages and ADX signals. The ETF generates weekly dividends but faces significant price erosion, down over 75% from prior levels. Recent news highlights concerns about uncapped losses despite high distributions, with performance heavily tied to underlying Strategy (MSTR) stock volatility.
The outlook remains risky due to structural erosion of NAV from distributions, reliance on volatile option premiums, and negative sentiment. While high yields attract income seekers, total returns have been negative, emphasizing caution. Key risks include Strategy stock performance, unsustainable payout funding, and market skepticism about long-term viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
